J. THORNTON to Narcotic Antagonists
This is a "connection" page, showing publications J. THORNTON has written about Narcotic Antagonists.
Connection Strength
2.470
-
Concurrent Depression Management in Patients with Opioid Use Disorder Undergoing Buprenorphine Therapy: Association with Buprenorphine Discontinuation. J Dual Diagn. 2025 Apr; 21(2):142-151.
Score: 0.898
-
Impact of COVID-19 Related Policy Changes on Buprenorphine Dispensing in Texas. J Addict Med. 2020 12; 14(6):e372-e374.
Score: 0.665
-
Understanding the financial barriers to treatment among individuals with opioid use disorder: a focus group study. Harm Reduct J. 2024 Dec 20; 21(1):220.
Score: 0.220
-
Patients' willingness to pay for naloxone: A national cross-sectional survey of prescription opioid users with chronic pain in the United States. J Am Pharm Assoc (2003). 2024 May-Jun; 64(3):102062.
Score: 0.208
-
Intention to get naloxone among?patients prescribed opioids for chronic pain. Harm Reduct J. 2022 Sep 22; 19(1):104.
Score: 0.189
-
Applying the capability, opportunity, motivation, and behavior model to identify opportunities to increase pharmacist comfort dispensing naloxone in Texas: A structural equation modeling approach. Int J Drug Policy. 2020 09; 83:102827.
Score: 0.161
-
Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia. J Am Pharm Assoc (2003). 2017 Mar - Apr; 57(2S):S12-S18.e4.
Score: 0.128